Enrico Martin

102 Chapter 5 30. Spiliopoulos K, Williams Z. Brachial plexus reconstruction following resection of a malignant peripheral nerve sheath tumor: Case report. Neurosurgery . 2011;69(1):E245-E250. doi:10.1227/ NEU.0b013e31821867de 31. Martin E, Dullaart MJ, van de Sande MAJ, van Houdt WJ, Schellekens PPA, Coert JH. Resuscitating extremities after soft tissue sarcoma resections: Are functional reconstructions an overlooked option in limb salvage? A systematic review. Eur J Surg Oncol . 2019;in press. doi:https://doi. org/10.1016/j.ejso.2019.05.024 32. Wasif N, Smith CA, Tamurian RM, et al. Influence of physician specialty on treatment recommendations in the multidisciplinary management of soft tissue sarcoma of the extremities. JAMA Surg . 2013;148(7):632-639. doi:10.1001/ jamasurg.2013.113 33. Davis A, O’Sullivan B, Turcotte R, et al. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol . 20 05;75 (1) :4 8 -53. doi:10.1016 / j. radonc.2004.12.020 34. Haas RL, Gronchi A, van de Sande MAJ, et al. Perioperative Management of Extremity Soft Tissue Sarcomas. J Clin Oncol . 2018;36(2):118-124. doi:10.1200/ JCO.2017.74.7527 35. Evans GRD, Brandt K. Peripheral nerve regeneration: the effects of postoperative irradiation. Plast Reconstr Surg . 2003;111(6):2023-2024. doi:10.1097/01. PRS.0000056837.37545.58 36. Adjuvant chemotherapy for localised resec table sof t tissue sarcoma in adul t s. Cochrane database Sy s t R e v . 20 0 0 ; (4) : CD0 01419. doi:10.1002/14651858.CD001419 37. Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer . 2008;113(3):573-581. doi:10.1002/ cncr.23592 38. Gortzak E, Azzarelli A, Buesa J, et al. A randomised phase II study on neo- adjuvant chemotherapy for “high-risk” adult soft-tissue sarcoma. Eur J Cancer . 2001;37(9):1096-1103. 39. Woll PJ, Reichardt P, Le Cesne A, et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol . 2012;13(10):1045-1054. doi:10.1016/S1470-2045(12)70346-7 40. Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft- tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol . 2014;15(4):415- 423. doi:10.1016/S1470-2045(14)70063-4 41. Kroep JR, Ouali M, Gelderblom H, et al. First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study. Ann Oncol Off J Eur Soc Med Oncol . 2011;22(1):207-214. doi:10.1093/annonc/mdq338 42. Loong HH, Wong K-H, Tse T. Controversies and consensus of neoadjuvant chemotherapy in soft-tissue sarcomas. ESMO open . 2018;3(Suppl 1):e000293. doi:10.1136/esmoopen-2017-000293 43. Carli M, Ferrari A, Mattke A, et al. Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. J Clin Oncol . 2005;23(33):8422-8430. doi:10.1200/ JCO.2005.01.4886 44. Shurell-Linehan E, DiPardo BJ, Elliott IA, et al. Pathologic Response to Neoadjuvant Therapy is Associated With Improved Long-term Survival in High-risk Primary Localized Malignant Peripheral Nerve Sheath Tumors. Am J Clin Oncol . 2019;42(5):426-431. doi:10.1097/ COC.0000000000000536